Article
Immune tolerance induction in patients with hemophilia A.
Thrombosis research - 1 Jan 2011
Astermark Jan
Abstract excerpt
Replacement therapy with factor VIII (FVIII) concentrates has become the mainstay of treatment for hemophilia, but about 30% of patients with a severe disease develop neutralizing antibodies against FVIII, which can lead to treatment resistance and an increased risk of bleeding. Immune tolerance induction (ITI) overcomes the immune response to FVIII concentrates in the majority of patients. Several factors may...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
